Another combination of favezelimab (anti-LAG-3) plus pembrolizumab in 80 MSS CRC patients in a phase 1 trial reported an overall ORR of 6.3% (5/80), with a higher response rate (11% [4/36]) in the PD-L1 CPS ≥ 1 population [33]. This evidence concerns the gene LAG3 and colorectal carcinoma.